Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant.
Prophylactic closure of the patent ductus arteriosus (PDA) has been recommended as a means of decreasing early respiratory distress, and thereby chronic respiratory sequelae in the very low birth weight (VLBW) neonate. This study was undertaken to evaluate some possible mechanisms for the observed failure of early indomethacin therapy to achieve such improvement. 24 VLBW infants with echocardiographic evidence of PDA were randomized to receive either indomethacin or placebo at 48 h of life; and then they were studied for clinical, metabolic and laboratory signs of ductal constriction and/or reopening. Early indomethacin conferred no improvement in respiratory sequelae. However, this was not secondary to a short-term therapeutic failure. Prophylactic indomethacin, even in the VLBW infant, was successful in decreasing dilator prostaglandin production, and probably in closing the PDA and in decreasing the number of recurrences. The implications are that even with effective ductal constriction, overall morbidity is not affected.
Hammerman
C
C
University of Chicago, Department of Pediatrics, Ill.
Strates
E
E
Komar
K
K
Bui
K
K
D004311:Double-Blind Method; D004374:Ductus Arteriosus, Patent / Q000097:blood / Q000188:drug therapy*; D004452:Echocardiography; D005500:Follow-Up Studies; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D011453:Prostaglandins / Q000097:blood; D011863:Radioimmunoassay; D011897:Random Allocation; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control*
D011453:Prostaglandins; D007213:Indomethacin